European Reference on Rare Adult Solid Cancer (ERN-EURACAN)
European Reference Network – Cancer
EURACAN is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States and funded by the EU’s 3rd Health Programme fostering health in Europe by encouraging cooperation between Member States to improve health policies that benefit their citizens. The programme aims to support and complement Member States’ health initiatives.
01/03/2017 – 28/02/2022 (5 years)
Centre Léon BérardVIEW PARTNERS >
Why it matters
There are more than 4 million people affected by rare cancers in the EU, representing about 24% of all cancer cases diagnosed in the 28 Member States each year. These are identified as those with an incidence of less than 6 per 100 000 people per year. The European Reference Network (ERN) on Rare Adult Solid Cancers (EURACAN) is a network connecting healthcare providers and centres of expertise covering highly specialised healthcare, for the purpose of improving access to diagnosis, treatment and the provision of high-quality healthcare for rare adult solid cancer patients in Europe. EURACAN splits rare cancers into 10 domains corresponding to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD10) and RARECARE.
“The JARC and the ERNs undoubtedly represent game-changing advances in rare cancer treatment and it is imperative to ensure their sustainability”
What ECPC does
ECPC is an elected European Patient Advocacy Group (ePAG) member representing rare adult solid cancer patients across the 10 rare cancer domains by actively participating in the EURACAN Board and Steering Committee. ECPC is also the Co-Lead in the Transversal Task Force on Dissemination and Communication and is represented in the EURACAN Task Force on research. ECPC counts on the expertise and collaboration of rare cancer patient organisations all over Europe to continuously represent the rare cancer patient community.
This project is funded by the European Union